$SYRE
Spyre Therapeutics, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021041216 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $13.70M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.822M $4.690M $4.460M
YoY Change 45.46% 22.77% 36.39%
% of Gross Profit
Research & Development $13.58M $16.87M $14.56M
YoY Change -19.51% 13.91% 1.2%
% of Gross Profit
Depreciation & Amortization $393.0K $230.0K $154.0K
YoY Change 70.87% 109.09% 54.0%
% of Gross Profit
Operating Expenses $20.40M $21.56M $14.56M
YoY Change -5.38% 15.78% -17.53%
Operating Profit -$6.705M -$21.56M -$19.02M
YoY Change -68.9% 15.78% 7.73%
Interest Expense $19.00K $160.0K $300.0K
YoY Change -88.13% -74.19% -41.18%
% of Operating Profit
Other Income/Expense, Net -$33.00K $142.0K $294.0K
YoY Change -123.24% -76.45% -40.0%
Pretax Income -$6.738M -$21.42M -$18.73M
YoY Change -68.54% 18.86% 9.09%
Income Tax $92.00K
% Of Pretax Income
Net Earnings -$6.830M -$21.42M -$18.73M
YoY Change -68.11% 18.86% 9.09%
Net Earnings / Revenue -49.87%
Basic Earnings Per Share -$0.10
Diluted Earnings Per Share -$0.10 -$404.6K -$565.9K
COMMON SHARES
Basic Shares Outstanding 65.63M 29.09M
Diluted Shares Outstanding 65.63M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.4M $157.7M $50.49M
YoY Change -17.31% 49.45% -59.18%
Cash & Equivalents $36.61M $65.71M $14.09M
Short-Term Investments $93.81M $92.02M $36.40M
Other Short-Term Assets $5.790M $4.100M $5.300M
YoY Change 41.22% -6.82% 70.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $134.4M $161.9M $54.30M
YoY Change -16.99% 47.24% -57.18%
LONG-TERM ASSETS
Property, Plant & Equipment $9.220M $4.896M $9.000M
YoY Change 88.32% 431.6% 429.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.394M $92.00K $1.600M
YoY Change 3589.13% -23.33% 1500.0%
Total Long-Term Assets $12.61M $11.05M $10.50M
YoY Change 14.21% 46.12% 517.65%
TOTAL ASSETS
Total Short-Term Assets $134.4M $161.9M $54.30M
Total Long-Term Assets $12.61M $11.05M $10.50M
Total Assets $147.0M $172.9M $64.80M
YoY Change -15.0% 47.17% -49.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.221M $4.151M $3.600M
YoY Change -46.49% 52.39% 12.5%
Accrued Expenses $12.85M $11.70M $13.50M
YoY Change 9.85% 13.59% 56.98%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.60M $15.89M $17.10M
YoY Change 29.67% 22.05% 44.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $200.0K $68.00K $4.800M
YoY Change 194.12% 51.11% 1100.0%
Total Long-Term Liabilities $200.0K $68.00K $4.800M
YoY Change 194.12% 51.11% 860.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.60M $15.89M $17.10M
Total Long-Term Liabilities $200.0K $68.00K $4.800M
Total Liabilities $27.96M $20.65M $22.00M
YoY Change 35.37% 15.52% 80.33%
SHAREHOLDERS EQUITY
Retained Earnings -$301.1M -$235.3M -$213.8M
YoY Change 27.96% 54.8%
Common Stock $420.1M $387.5M
YoY Change 8.41% 54.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $119.0M $152.3M $42.81M
YoY Change
Total Liabilities & Shareholders Equity $147.0M $172.9M $64.80M
YoY Change -15.0% 47.17% -49.57%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$6.830M -$21.42M -$18.73M
YoY Change -68.11% 18.86% 9.09%
Depreciation, Depletion And Amortization $393.0K $230.0K $154.0K
YoY Change 70.87% 109.09% 54.0%
Cash From Operating Activities $2.082M -$19.42M -$21.69M
YoY Change -110.72% 18.56% 37.24%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K -$1.320M $1.389M
YoY Change -97.73% 2100.0% 1077.12%
Acquisitions
YoY Change
Other Investing Activities -$47.33M -$55.43M $16.14M
YoY Change -14.61% 32.13% 14.88%
Cash From Investing Activities -$47.36M -$56.76M $14.75M
YoY Change -16.56% 35.08% 5.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $129.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -190.0K 129.3M 282.0K
YoY Change -100.15% -40506.25% -99.57%
NET CHANGE
Cash From Operating Activities 2.082M -19.42M -21.69M
Cash From Investing Activities -47.36M -56.76M 14.75M
Cash From Financing Activities -190.0K 129.3M 282.0K
Net Change In Cash -45.47M 53.12M -6.659M
YoY Change -185.59% -190.46% -110.54%
FREE CASH FLOW
Cash From Operating Activities $2.082M -$19.42M -$21.69M
Capital Expenditures -$30.00K -$1.320M $1.389M
Free Cash Flow $2.112M -$18.10M -$23.08M
YoY Change -111.67% 10.91% 44.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2274000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
200000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13696000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9151000
us-gaap Operating Expenses
OperatingExpenses
40582000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40582000
us-gaap Investment Income Net
InvestmentIncomeNet
461000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-25000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
436000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6738000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40146000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6844000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1757000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18218000
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5530000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13696000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21245000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25048000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40158000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43019670
us-gaap Net Income Loss
NetIncomeLoss
-40146000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
6000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
224000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-42000
CY2021Q2 us-gaap Liabilities
Liabilities
27958000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-52000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-83000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
142000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49025956
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49025956
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
420064000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301056000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
119024000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146982000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13579000
us-gaap Operating Expenses
OperatingExpenses
38610000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21560000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24914000
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
19000
CY2020Q2 us-gaap Investment Income Net
InvestmentIncomeNet
161000
us-gaap Investment Income Net
InvestmentIncomeNet
41000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7804000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3941000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21418000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24956000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65631906
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52941603
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65618207
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-21418000
us-gaap Net Income Loss
NetIncomeLoss
-25048000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
173000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
123755000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2080000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6830000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
119024000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
60081000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
174000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
115000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1348000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-185000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-18728000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
42805000
CY2020Q2 agle Stock Issued During Period Value Common Stock And Pre Funded Warrants
StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants
129054000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1600000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
173000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-21418000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
152258000
us-gaap Profit Loss
ProfitLoss
-25048000
us-gaap Profit Loss
ProfitLoss
-40146000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
753000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
376000
agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
405000
agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
-19000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-341000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
58000
us-gaap Share Based Compensation
ShareBasedCompensation
3837000
us-gaap Share Based Compensation
ShareBasedCompensation
2948000
agle Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
219000
agle Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
306000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
15000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2876000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1637000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-55000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1318000
agle Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-155000
agle Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-277000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1867000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17448000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41107000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
480000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2714000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
93579000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
75500000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
56000000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
36206000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38059000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42008000
agle Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
129250000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
403000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
333000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
233000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
8000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
170000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129575000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-55326000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
91937000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20753000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36611000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
46460000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67213000
agle Leased Assets Obtained In Exchange For Lease Obligations
LeasedAssetsObtainedInExchangeForLeaseObligations
872000
agle Leased Assets Obtained In Exchange For Lease Obligations
LeasedAssetsObtainedInExchangeForLeaseObligations
176000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
23000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
440000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301100000
CY2021Q2 agle Cash Cash Equivalents Marketable Securities And Restricted Cash
CashCashEquivalentsMarketableSecuritiesAndRestrictedCash
130400000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q2 agle Number Of Subsidiary Corporations Owned
NumberOfSubsidiaryCorporationsOwned
9
CY2021Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
21856000
CY2021Q2 agle Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
1000
CY2021Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
21855000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
93826000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
18000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
93813000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
77600000
CY2020Q4 agle Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
3000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
77597000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
56183000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2021Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
52746000
CY2021Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
19000
CY2021Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
52746000
CY2021Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
19000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
110076000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
10000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
110076000
CY2020Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
10000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
93813000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
93813000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
56178000
CY2021Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2899000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3712000
CY2021Q2 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
6804000
CY2020Q4 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
8620000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1606000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1074000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1132000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
464000
CY2021Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12441000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13870000
CY2020Q2 agle Reduction In Exercise Price Of Each Warrant From Public Offering Price For Pre Funded Warrants Per Share
ReductionInExercisePriceOfEachWarrantFromPublicOfferingPriceForPreFundedWarrantsPerShare
0.0001
CY2020Q2 agle Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised
MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised
0.0499
CY2020Q2 agle Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised To Certain Holders
OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders
0.0999
agle Period After Notice Received By Company Maximum Ownership Percentage To Be Effective Description
PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription
The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
21500000
agle Contract With Customer Liability Deductions Through Contracts Acquired
ContractWithCustomerLiabilityDeductionsThroughContractsAcquired
13696000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7804000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2021Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2020Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0

Files In Submission

Name View Source Status
0001564590-21-041216-index-headers.html Edgar Link pending
0001564590-21-041216-index.html Edgar Link pending
0001564590-21-041216.txt Edgar Link pending
0001564590-21-041216-xbrl.zip Edgar Link pending
agle-10q_20210630.htm Edgar Link pending
agle-10q_20210630_htm.xml Edgar Link completed
agle-20210630.xsd Edgar Link pending
agle-20210630_cal.xml Edgar Link unprocessable
agle-20210630_def.xml Edgar Link unprocessable
agle-20210630_lab.xml Edgar Link unprocessable
agle-20210630_pre.xml Edgar Link unprocessable
agle-ex311_6.htm Edgar Link pending
agle-ex312_183.htm Edgar Link pending
agle-ex321_7.htm Edgar Link pending
agle-ex322_184.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending